SCHEDULE 13G/A: ADAR1 Entities Maintain 9.99% Passive Stake in Grace Therapeutics, Inc.

ADAR1 Capital Management, its general partner, and Daniel Schneeberger have filed an amended Schedule 13G, reaffirming a 9.99% beneficial ownership stake in Grace Therapeutics, Inc., primarily through common stock and warrants.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Grace Therapeutics, Inc.
• Each reporting person maintains a 9.99% beneficial ownership stake in Grace Therapeutics, Inc. Common Stock.
• ADAR1 Capital Management, LLC and Daniel Schneeberger beneficially own 1,501,473 shares.
• ADAR1 Capital Management GP, LLC beneficially owns 1,502,143 shares.
• The reported ownership includes direct common stock holdings (e.g., 183,779 shares by ADAR1 Partners, LP and 6,033 shares by Spearhead Insurance Solutions IDF, LLC) and shares underlying pre-funded and milestone warrants.
• A substantial number of shares underlying warrants (2,932,081 for ADAR1 Capital Management/Schneeberger and 2,416,088 for ADAR1 Capital Management GP) are excluded from the reported beneficial ownership due to a 9.99% beneficial ownership limitation on their exchange and exercise.
• The beneficial ownership percentage is calculated based on 13,718,106 shares of Grace Therapeutics, Inc. Common Stock outstanding as of March 7, 2025, as reported in the Issuer's S-3 filing.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing indicates a significant, passive institutional investment, which can be seen as a vote of confidence. However, it's a routine disclosure and doesn't provide new operational or financial performance data for Grace Therapeutics itself. The 9.99% limitation on warrant exercise is a neutral structural detail.

Positives

• The continued significant institutional investment by ADAR1 Capital Management suggests ongoing confidence in Grace Therapeutics, Inc.
• The passive nature of the investment (Schedule 13G filing) indicates that the investor is not seeking to influence or change control of the company, which can provide stability.

Negatives

• The 9.99% beneficial ownership limitation on the exercise of warrants prevents the reporting persons from immediately converting a larger portion of their potential holdings, which could cap their immediate upside from warrant exercise.

Risks

• The existence of a large number of unexercised warrants (over 2.9 million shares for some entities) could lead to future dilution if these warrants are exercised beyond the current 9.99% limitation, should that limitation be removed or exceeded.

Future Outlook

This filing is a passive ownership disclosure and does not contain forward-looking statements or guidance from Grace Therapeutics, Inc. It primarily reflects the current beneficial ownership structure of the reporting entities and their intent to hold the securities in the ordinary course of business.

Management Comments

• Daniel Schneeberger, as Manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, and in his individual capacity, certified that 'the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.'

Industry Context

This Schedule 13G filing indicates a significant passive investment by ADAR1 Capital Management in Grace Therapeutics, Inc. Such filings are common in the financial industry, reflecting institutional investors taking substantial, but non-controlling, positions in publicly traded companies. The 9.99% ownership cap is a common strategy to avoid certain regulatory burdens associated with higher ownership thresholds or activist intent, particularly the more stringent reporting requirements of a Schedule 13D.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory disclosure of passive beneficial ownership. It does not contain performance metrics or operational results that would allow for a direct comparison to industry-specific benchmarks or competitor performance.
• The ownership percentage of 9.99% is a common threshold for passive investors to maintain compliance with SEC rules (e.g., avoiding Schedule 13D filing requirements which imply activist intent) while holding a significant stake. This is a standard practice for institutional investors seeking to hold a substantial position without triggering activist reporting obligations.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holder like ADAR1 Capital Management may be viewed positively, signaling institutional confidence in Grace Therapeutics. The existence of warrants, if exercised, could lead to future dilution, but this is currently capped by the 9.99% limitation, mitigating immediate concerns.

Next Steps

• The document does not specify any future actions or milestones for Grace Therapeutics, Inc. or the reporting persons beyond the ongoing passive ownership.

Key Dates

Keywords

Grace Therapeutics Inc., ADAR1 Capital Management LLC, ADAR1 Capital Management GP LLC, Daniel Schneeberger, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Institutional Investment